IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/590,441

Applicant Filed

Hirokazu Inoue August 23, 2006

Title

METHOD OF INDUCING HOMOLOGOUS

RECOMBINATION

Customer No.

000,116

Docket No.

41066

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

This communication is in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures (form PCT/DO/EO/922) dated May 4, 2007. A copy of that Notice is enclosed. The Notice set a two-month period for response, which will expire July 4, 2007.

The Notice indicated that applicant must provide the following:

- 1. Computer Readable Form ("CRF") of the "Sequence Listing,"
- 2. Paper or compact-disc copy of the Sequence Listing,
- 3. An amendment specifically directing its entry into the application, and
- 4. A statement that the content of the sequence listing information recorded in the CRF is identical to the written (paper or compact-disc copy) Sequence Listing.

With respect to items 1-2 and 4 above, these were already filed on entry into the U.S. national-phase. Please see the enclosed copy of our return-receipt postcard, which was date-stamped by the USPTO on August 23, 2006 acknowledging receipt by the USPTO of, among other things:

- Seq. Listing (17 pgs.)
- CD-ROM (2 copies)
- Statement regarding computer readable form of sequence listing

The 17-page Sequence Listing mentioned above, which was received by the USPTO, was the written Sequence Listing required by 37 CFR § 1.821(c). The CD-ROMs mentioned above, also received by the USPTO, are two copies of the CRF of the Sequence Listing, required under 37 CFR § 1.821(e). Please note they were labeled "Copy 1 of 2" and "Copy 2 of 2," and are two complete copies of the CRF; see attached Exhibit A. Finally, the Statement regarding computer readable form of sequence listing, also received by the USPTO, was the statement required by 37 CFR § 1.821(f).

Regarding item 3 above, after consultation with Mr. Brian Lin of the PCT Legal Office at the USPTO, it is believed that no amendment directing entry of the Sequence Listing into the application is required. The Sequence Listing was part of PCT application PCT/JP2004/012516 (of which the present application is the U.S. national phase), and accordingly has been made available to the USPTO by the International Bureau. Because the Sequence Listing was part of the PCT application, it constitutes part of the U.S. application on entry into the U.S. national phase, and no amendment directing its entry is believed to be required.

If there are any questions regarding this submission, please contact Mr. Brian Lin of the PCT Legal Office (phone – 571-272-3303) or the undersigned.

If there are any fees resulting from this communication, please charge said fees to Deposit Account No. 16-0820, Order No. 41066.

Respectfully submitted,

PEARNE & GORDON LLP

Steven J. Solomon, Reg. No. 48719

1801 East 9th Street Suite 1200 Cleveland, Ohio 44114-3108 (216) 579-1700

Date: June 20, 2007



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. DOX 1450 Alexandria, Virginia 22313-1450

OC000000023677981

	www.uspto.gov		
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICAN	ATTY. DOCKET NO.	
10/590,441 116 PEARNE & GORDON LLP	Hirokazu Inoue	41066	
	And the second s	INTERNATIONAL APPLICATION NO.	
		PCT/JP04/12516	
		I.A. FILING DATE PRIORITY DATE	
1801 EAST 9TH STREET	The second secon	08/31/2004	
SUITE 1200	MAY 67 2007		
CLEVELAND, OH 44114-3108		CONFIRMATION NO. 6096	
	The state of the s	371 FORMALITIES LETTER	
	Report Transport of the State o		

Date Mailed: 05/04/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

COPY

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/Authenticate/SerLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/590,441	PCT/JP04/12516	41066

FORM PCT/DO/EO/922 (371 Formalities Notice)

ARTIFACT SHEET

Enter a	rtifact number below. Artifact number is application number +
artifact	type code (see list below) + sequential letter (A, B, C). The first
artifact	folder for an artifact type receives the letter A, the second B, etc
Examp	les: 59123456PA, 59123456PB, 59123456ZA, 59123456ZB
1	10/590441 SA
Indicat	e quantity of a single type of artifact received but not scanned. Create
individ	and artifact folder/how and artifact received but not scanned. Create
marvia	ual artifact folder/box and artifact number for each Artifact Type.
10	CD(s) containing:
·	computer program listing
	Doc Code: Computer Artifact Type Code: P
	pages of specification
	and/or sequence listing
	and/or table
	Doc Code: Artifact Artifact Type Code: S
•	content unspecified or combined
	Doc Code: Artifact Artifact Type Code: U
	Stapled Set(s) Color Documents or B/W Photographs
	Doc Code: Artifact Type Code: C
	Microfilm(s)
	Doc Code: Artifact Type Code: F
	Video tape(s)
	Doc Code: Artifact Type Code: V
	Model(s)
	Doc Code: Artifact Type Code: M
j.	Bound Document(s)
	Doc Code: Artifact Type Code: B
	J. Comments of the comments of
1 1	Confidential Information Disclosure Statement or Other Documents
	marked Proprietary, Trade Secrets, Subject to Protective Order,
	Material Submitted under MPEP 724.02, etc.
	Doc Code: Artifact Artifact Type Code X
	200 0000. Fitthact Type Code A
	Other description:
	Other, description: Doc Code: Artifact Type Code: 7.
	Doc Code: Artifact Type Code: Z

March 8, 2004

	3V2/3
Express Mail: EV740 232055US	No. OUA 1 A
THICK HILL INDUC	*
method of inducing hom	1010gous recombination
TRN	atent NoDate:
Filed: Herewith E	xaminer:
Enclosed Are:	Priority Documentslisted below
PATENT APPLICATION (PCT-based)	other CCT+. O+ EXPRESS I ICII
New Application Transmittal (PTD-1394)(X 2)	Homends according to Hrt. 64
	of PCT (2,0%); SOEC. (3-10%);
Eee Transmittal (in duplicate)	Abstract / los 1. Statement
Application Data Sheet (3PP.)	reagroups computer readable
Declaration & Power Of Attorneypgs.	form of sequence listing:
Pgs. of Claims	CHECK(S) IN THE AMOUNT(S) OF A - ROM Tacons
Sheet(s) of Drawing(s)	\$\$ Say Ishnal na
Formal Informal	Wing 1- And The Kall Mark
	Client Coc 41066 _ Doc. No.
Continuation or Division	int. SJS /alw Date 8/23/06
	Int. See See See See See See See See See Se
ASSIGNMENTpgsTransmittal(s)Copies Unformation disclosure (309) PTO-1449 Refs.	ACKNOWLEDGES RECEIPT OF:
Transmittal(s)	A DOT/DTA Z.3 ALII A/UUD
Original Copies APD REC	a Latitud Man 119 a zaza
E WEST MATION DIECE OF THE (3/8.)	orano ana sa sa sa
INFORMATION DISCLOSURE CO.	
Alama Vinci Cinh sace	\ 1U/J7U44L
MAMENDMENT HOPE! JUINCI. Sub. Spece	y ······
: Busines to Coper No. 101 H	





PEARNE & GORDON LLP

1801 EAST 9TH STREET


SUITE 1200

CLEVELAND, OHIO 44114-3108

14/3105

hladaladadhadahahadhadhadhadhadh





EXHIBIT